Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

92.57 -0.51 (-0.55%)
Official Closing Price Updated: 7:00 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,054,610
Open 92.85
Bid (Size) 92.00 (3)
Ask (Size) 94.15 (2)
Prev. Close 93.08
Today's Range 92.35 - 92.91
52wk Range 92.19 - 108.78
Shares Outstanding N/A
Dividend Yield 3.75%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
Sustained efficacy with Novartis' Kesimpta for up to 6 years in recently diagnosed relapsing multiple sclerosis. Significant reductions in relapses, MRI lesions, and disability worsening observed. 
Via Benzinga
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
These income stocks look like good options at current levels. 
Via The Motley Fool

Performance

YTD
-8.35%
-8.35%
1 Month
-3.89%
-3.89%
3 Month
-14.31%
-14.31%
6 Month
-2.19%
-2.19%
1 Year
-5.56%
-5.56%

More News

Read More
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Via Benzinga
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
Via The Motley Fool
Topics ETFs
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Via Benzinga
Looking At Novartis's Recent Unusual Options Activity
Via Benzinga
Novartis AG (NYSE: NVS) Highlighted for Surprising Price Action
Via Investor Brand Network
1 Magnificent Dividend Stock to Buy and Hold
Via The Motley Fool
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Via Investor's Business Daily
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
From Arvinas Inc.
Via GlobeNewswire
Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday?
Via Benzinga
SOUN Stock Alert: The $150 Million Reason SoundHound AI Is Down Today
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Jack Ma Is Giving Alibaba (BABA) Stock a Big Boost
Via InvestorPlace
Novartis Layoffs 2024: What to Know About the Latest NVS Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says
Via Benzinga
Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report
Via Benzinga
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
Via Benzinga
Exposures Product Safety
Why Is Novartis Stock Trading Higher On Thursday?
Via Benzinga
Harnessing AI for Drug Discovery: Top 3 Stocks to Watch
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Magnificent 7 Stocks Become The Star Attractions For Norway's Sovereign Wealth Fund
Via Benzinga
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Via Talk Markets
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
Via Benzinga
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
Via Benzinga
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.